𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets

✍ Scribed by Hamid Morjani; Nasséra Aouali; Rajae Belhoussine; Robert Jan Veldman; Thierry Levade; Michel Manfait


Publisher
John Wiley and Sons
Year
2001
Tongue
French
Weight
261 KB
Volume
94
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Multidrug-resistant (MDR) cancer cells have been shown to have an accumulation of glucosylceramide (GlcCer). In this study, we aim at localizing, at subcellular level, where these lipids accumulate. Neutral lipids and phospholipid containing organelles have been identified using confocal fluorescence microscopy and microspectrofluorometry by monitoring the emission of the fluorescent probe Nile-red. Data from confocal fluorescence microscopy analysis shows accumulation of neutral lipids in cytoplasmic droplets of MDR human carcinoma MCF7R cells. Microspectrofluorometric measurements show an increase of the gold-yellow emission intensity in MCF7R cells, corresponding to neutral lipids. Similar observations were made in human MDR vincristine-HL60 and doxorubicin-KB selected cells. Total cellular glucosylceramide (GlcCer) measurements using [ 3 H]-palmitic acid and thin layer chromatography show a significant increase of GlcCer in MCF7R cells. Moreover, MCF7R cells treated with fluorescent GlcCer-bodipy exhibit an accumulation of this lipid in cytoplasmic droplets. Treatment of MCF7R cells with 1-phenyl-2-palmitoylamino-3-morpholino-1-propanolol (PPMP), a potent inhibitor of GlcCer synthase, attenuates the Nile-red fluorescence emission emanating from these structures and reverses MDR. Moreover, Golgi compartments stained with fluorescent PPMP-bodipy, show an increase in the Golgi compartments density. Treatment of MCF7R cells with cyclosporine A (CSA), tamoxifen (TMX) and 3-azido-3deoxythymidine (AZT) leads to the same effect observed in the presence of PPMP. Treatment of MCF7 and MCF7R with the ␤-glucosidase inhibitor conduritol ␤-epoxide (CBE) significantly increases resistance to daunorubicin only in MCF7R cells. These data demonstrate also that: (i) CSA, an inhibitor of MDR, has an additional target in addition to P-glycoprotein; and (ii) TMX (used in breast cancer treatment and prevention) and AZT (used in the treatment of HIV) could have side effects by disturbing lipid metabolism and inhibiting many cellular functions required in normal cells.


📜 SIMILAR VOLUMES


MRP1 and glucosylceramide are coordinate
✍ Karin Klappe; John W.J. Hinrichs; Bart-Jan Kroesen; Hannie Sietsma; Jan Willem K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 295 KB

## Abstract Previously we have described a novel multidrug‐resistant cell line, HT29^col^, which displayed over expression of the multidrug‐resistance protein 1 (MRP1) and an altered sphingolipid composition, including enhanced levels of glucosylceramide (GlcCer; Kok JW, Veldman RJ, Klappe K, Konin

Multidrug resistance modulators and doxo
✍ Anthony Lucci; Tie-Yan Han; Yong-Yu Liu; Armando E. Giuliano; Myles C. Cabot 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

## BACKGROUND. To provide insight for the development of more effective clinical agents, the authors attempted to elucidate the mechanisms of action of multidrug resistance (MDR) modulators. Previously, the authors found that MDR modulators blocked the conversion of ceramide to glucosylceramide in

Changes in phospholipase D isoform activ
✍ Giusy Fiucci; Malgorzata Czarny; Yaakov Lavie; Di Zhao; Brygida Berse; J. Krzysz 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 171 KB

Multidrug resistance (MDR) is a major cause of failure of cancer chemotherapy and is often associated with elevated expression of drug transporters such as P-glycoprotein (P-gp) in the cancer cells. MDR is, however, accompanied by additional biochemical changes including modifications of membrane co

Reduced drug accumulation and multidrug
✍ Jong Seok Lee; Stefania Scala; Yoshihito Matsumoto; Bruce Dickstein; Rob Robey; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB

MCF-7 human breast cancer cells selected in Adriamycin in the presence of verapamil developed a multidrug resistant phenotype, which was characterized by as much as 100,000-fold resistance to mitoxantrone, 667-fold resistance to daunorubicin, and 600-fold resistance to doxorubicin. Immunoblot and PC